Mar. 16 at 3:09 PM
Three days after ITCI settled its patent litigation with Sandoz (locking out generics until 2040),
$JNJ paid
$14.6B (~21.5x revenue) to acquire it. Apply that same multiple to
$ESPR's ~
$160M US recurring revenue and you get a SP of roughly
$13.
The current price is
$2.50. That math excludes the Corstasis revenue, Japan and Europe royalties, the 2027 triple combo pipeline, and
$500M+ in remaining partner milestones.
